Regeneron Pharmaceuticals, Inc. Website

Regeneron Pharmaceuticals, Inc.

NasdaqGS-REGN

Basic

  • Market Cap

    $117.12B

  • EV

    $102.33B

  • Shares Out

    107.89M

  • Revenue

    $13.1B

  • Employees

    13,677

Margins

  • Gross

    51.31%

  • EBITDA

    33.77%

  • Operating

    30.45%

  • Pre-Tax

    30.85%

  • Net

    29.45%

  • FCF

    31.03%

Returns (5Yr Avg)

  • ROA

    21.35%

  • ROTA

    29.78%

  • ROE

    29.58%

  • ROCE

    27.04%

  • ROIC

    31.1%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $1,063.05

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $10.52B

  • Net Debt

    -$14.8B

  • Debt/Equity

    0.1

  • EBIT/Interest

    56.1

Growth (CAGR)

  • Rev 3Yr

    12.51%

  • Rev 5Yr

    14.79%

  • Rev 10Yr

    19.05%

  • Dil EPS 3Yr

    -1.23%

  • Dil EPS 5Yr

    9.9%

  • Dil EPS 10Yr

    25.41%

  • Rev Fwd 2Yr

    6.77%

  • EBITDA Fwd 2Yr

    3.4%

  • EPS Fwd 2Yr

    3.81%

  • EPS LT Growth Est

    15.56%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Operating Revenues

6,383.6

7,940.1

15,790.5

11,807.8

12,581.1

12,563.1

Other Revenues, Total

174

557

281.2

365.1

536.1

537

Total Revenues

6,557.6

8,497.1

16,071.7

12,172.9

13,117.2

13,100.1

Total Revenues % Chg.

27.4%

29.6%

89.1%

-24.3%

7.8%

5.9%

Cost of Goods Sold, Total

3,215.1

3,766.9

5,297.6

5,152.9

6,254.8

6,378.3

Gross Profit

3,342.5

4,730.2

10,774.1

7,020

6,862.4

6,721.8

Selling General & Admin Expenses, Total

1,341.9

1,346

1,824.9

2,115.9

2,631.3

2,719.2

Other Operating Expenses

-209.2

-280.4

-45.6

-89.9

-2.1

13.7

Other Operating Expenses, Total

1,132.7

1,065.6

1,779.3

2,026

2,629.2

2,732.9

Operating Income

2,209.8

3,664.6

8,994.8

4,994

4,233.2

3,988.9

Interest Expense, Total

-30.2

-56.9

-57.3

-59.4

-73

-71.1

Interest And Investment Income

75.4

45.8

160.1

495.9

562.2

Net Interest Expenses

-30.2

18.5

-11.5

100.7

422.9

491.1

Currency Exchange Gains (Loss)

0.4

50.2

-12.9

-12.9

Other Non Operating Income (Expenses)

131.2

19.3

4

8.8

-20

-3.4

EBT, Excl. Unusual Items

2,310.8

3,702.4

8,987.7

5,153.7

4,623.2

4,463.7

Gain (Loss) On Sale Of Investments

118.3

196

386.1

-39.8

-237.8

-269.3

In Process R&D Expenses

-88

-48

-255.1

-186.1

-137.1

Other Unusual Items

-15.3

EBT, Incl. Unusual Items

2,429.1

3,810.4

9,325.8

4,858.8

4,199.3

4,042

Income Tax Expense

313.3

297.2

1,250.5

520.4

245.7

184.2

Earnings From Continuing Operations

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

3,857.8

Net Income

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

3,857.8

Net Income to Common Incl Extra Items

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

3,857.8

Net Income to Common Excl. Extra Items

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

3,857.8

Total Shares Outstanding

109.1

104

106.6

107

107.1

107.9

Weighted Avg. Shares Outstanding

109.2

107.6

105.7

107.1

106.7

106.9

Weighted Avg. Shares Outstanding Dil

114.6

115.1

112.2

113.5

113.7

114

EPS

19.4

32.7

76.4

40.5

37.1

36.1

EPS Diluted

18.5

30.5

72

38.2

34.8

33.8

EBITDA

2,420.1

3,900.5

9,281

5,335.4

4,654.2

4,424.5

Effective Tax Rate

12.9%

7.8%

13.4%

10.7%

5.9%

4.6%